title: [Recurrent vulvovaginal mycoses].
abstract: The treatment of recurrent vulvovaginal fungal infections is difficult. Pathogenic mechanisms are discussed. Available pharmacologic treatments and their mechanisms of action are reviewed. Patients clearly prefer oral treatment. Ketoconazole is toxic. Only topical or nonabsorbed oral agents can be used during pregnancy. Agents absorbed via the digestive tract can be used in women who use effective contraceptive methods. Published data demonstrate that trifluconazole (which has not yet been granted a license in France) is potent and less toxic than ketoconazole, and that recurrences at discontinuation of this drug are less common. A few hypotheses for future research are presented.
authors.affiliation: Service de Gynécologie-Obstétrique, Centre hospitalier, Thonon.
authors.forename: J
authors.initials: J
authors.lastname: Salvat
authors.forename: P
authors.initials: P
authors.lastname: Romand
authors.forename: A
authors.initials: A
authors.lastname: Vincent-Genod
authors.forename: B
authors.initials: B
authors.lastname: Younes
authors.forename: M
authors.initials: M
authors.lastname: Guilbert
mesh_terms: D000282:Administration, Intravaginal; D000284:Administration, Oral; D000935:Antifungal Agents / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D017060:Patient Satisfaction; D011247:Pregnancy; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents